Regeneron Pharmaceuticals To Buy 23andMe and Its Data For $256 Million

Regeneron Pharmaceuticals is acquiring most of 23andMe's assets for $256 million. The sale includes 23andMe's Personal Genome Service, Total Health and Research Services business lines. What's not included is 23andMe's telehealth unit, Lemonaid Health, which the company acquired for around $400 million in 2021. It'll be shut down, but all staffers will remain employed. CNBC reports: The deal is still subject to approval by the U.S. Bankruptcy Court for the Eastern District of Missouri. Pending approval, it's expected to close in the third quarter of this year, according to the release. In its bankruptcy proceedings, 23andMe required all bidders to comply with its privacy policies, and a court-appointed, independent 'Consumer Privacy Ombudsman' will assess the deal, the companies said.

Several lawmakers and officials, including the Federal Trade Commission, had expressed concerns about the safety of consumers' genetic data through 23andMe's sale process. The privacy ombudsman will present a report on the acquisition to the court by June 10. 'We are pleased to have reached a transaction that maximizes the value of the business and enables the mission of 23andMe to live on, while maintaining critical protections around customer privacy, choice and consent with respect to their genetic data,' Mark Jensen, 23andMe's board chair, said in a statement. 'At its peak, 23andMe was valued at around $6 billion,' notes the report.

Read more of this story at Slashdot.